Dementia

DiagnaMed Accelerates Commercialization Initiatives of CERVAI™ Brain Health AI Solution

Retrieved on: 
Monday, March 11, 2024

Based on research and development at Drexel University and the University of Miami, CERVAI™ combines a Brain Age™ Estimation and Brain Health Assessment tool with the aim to ‘raise a red flag’ for potential brain health issues.

Key Points: 
  • Based on research and development at Drexel University and the University of Miami, CERVAI™ combines a Brain Age™ Estimation and Brain Health Assessment tool with the aim to ‘raise a red flag’ for potential brain health issues.
  • CERVAI™ can assess if a brain is aging more quickly or more slowly than is typical for healthy individuals.
  • Brain health is scored by taking a clinically validated assessment for brain resilience, vulnerability and performance functions.
  • Fabio Chianelli, Chairman and CEO of DiagnaMed, commented: “We are pleased to be accepted into the HEALTHI program to accelerate our commercialization initiatives of CERVAI™, a novel brain health AI platform, and validate its potential in improving overall brain health.

Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference

Retrieved on: 
Friday, March 8, 2024

BOTHELL, Wash., March 08, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, presented new clinical and preclinical data further highlighting the therapeutic potential of fosgonimeton at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, being held in Lisbon, Portugal March 5 – 9, 2024.

Key Points: 
  • Fosgonimeton is a potentially first-in-class investigational small molecule designed to positively modulate the hepatocyte growth factor (HGF) system, which can activate neuroprotective, neurotrophic and anti-inflammatory pathways in the central nervous system.
  • “We believe safety and efficacy outcomes from the exploratory SHAPE Phase 2 clinical trial presented at this year’s AD/PD, along with previous clinical data, support the continued development of fosgonimeton.
  • These findings support the potential therapeutic benefit of modulating the neurotrophic HGF system with fosgonimeton for neurodegenerative diseases.
  • “We’re pleased to be presenting additional preclinical data highlighting the neuroprotective effects of fosgonimeton in models of both Alzheimer’s and Parkinson’s diseases at AD/PD 2024,” said Kevin Church, Ph.D., Chief Scientific Officer of Athira.

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

Retrieved on: 
Thursday, March 7, 2024

“Parkinson’s disease remains one of the most prevalent neurodegenerative diseases worldwide, affecting more than a million people in the U.S. alone.

Key Points: 
  • “Parkinson’s disease remains one of the most prevalent neurodegenerative diseases worldwide, affecting more than a million people in the U.S. alone.
  • The 201 Trial evaluating three doses of risvodetinib in untreated Parkinson’s patients is beginning to yield information about the experience of participants on risvodetinib,” said Dr. Werner.
  • Ten mild and one moderate adverse event that might be related to treatment have been reported across all study participants.
  • Depending on the date of enrollment of the last participant, top line results from the 201 Trial might be reported in the second-half of 2024.

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

Retrieved on: 
Tuesday, March 5, 2024

BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced the presentation of biomarker data from the AscenD-LB Phase 2a trial of neflamapimod in patients with dementia with Lewy bodies (DLB), demonstrating that neflamapimod reduces plasma levels of glial fibrillary acidic protein (GFAP) compared placebo, and that the effects of neflamapimod on GFAP were inversely correlated to change in CDR-SB (reduction in GFAP associated with improvement in CDR-SB, and increase in GFAP associated with worsening in CDR-SB). These data will be featured in a poster presentation at the 18th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024, being held both virtually and in Lisbon, Portugal from March 5–9, 2024. In addition, academic researchers from UCL will be presenting data in a separate poster at the meeting demonstrating that p38MAPK inhibition, including with neflamapimod specifically, improves tau-induced axonal transport defects both in vitro and in a tauopathy mouse model.

Key Points: 
  • These data will be featured in a poster presentation at the 18th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024, being held both virtually and in Lisbon, Portugal from March 5–9, 2024.
  • “The effects on GFAP, particularly the association between GFAP response and clinical outcomes, further support that neflamapimod is clinically efficacious in patients with DLB,” said John Alam, MD, Chief Executive Officer of CervoMed.
  • A PDF copy of the GFAP poster presentation will be available on the “ Presentations and Publications ” section of the CervoMed website.
  • Title: NEW INSIGHTS IN THE DEVELOPMENT OF BIOMARKERS, IMAGING, AND THERAPY OF ALPHA-SYNUCLEIN, LRKK2, AND GBA PATHOLOGIES

Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting

Retrieved on: 
Monday, March 4, 2024

The presentations include new data for its oral small molecule inhibitor of tau aggregation (BIIB113), as well as presentations providing insights into the underlying mechanisms of Alzheimer’s disease.

Key Points: 
  • The presentations include new data for its oral small molecule inhibitor of tau aggregation (BIIB113), as well as presentations providing insights into the underlying mechanisms of Alzheimer’s disease.
  • In addition to BIIB113, Biogen is researching the potential of tau reduction in AD with its investigational antisense oligonucleotide targeting the microtubule associated protein tau (MAPT) gene (BIIB080).
  • Oral presentation: Results of the first in-human, randomized, blinded, placebo-controlled, single- and multiple-ascending dose study of BIIB113 in healthy volunteers.
  • Oral presentation: Lecanemab for the treatment of early Alzheimer’s disease; the extension of efficacy results from Clarity AD.

REMSleep Holdings Shareholder Update

Retrieved on: 
Monday, March 4, 2024

CLEARWATER, FL, March 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - REMSleep Holdings, Inc. (OTC PINK: RMSL) gives an update on FDA process and REMSleep status.

Key Points: 
  • CLEARWATER, FL, March 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - REMSleep Holdings, Inc. (OTC PINK: RMSL) gives an update on FDA process and REMSleep status.
  • We have had numerous inquiries asking for REMSleep regulatory status update.
  • REMSleep consultants are confident we will receive our 510(K) and we will never give up until we are successful.
  • REMSleep has addressed this problem by developing a novel CPAP nasal pillow interface that has been engineered to reduce pressure and enable better airflow.

Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference

Retrieved on: 
Monday, March 4, 2024

AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced plans to present a virtual oral presentation at the International Conference on Alzheimer’s and Parkison’s Disease (AD/PD 2024) taking place in Lisbon, Portugal from March 5-9, 2024.

Key Points: 
  • AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced plans to present a virtual oral presentation at the International Conference on Alzheimer’s and Parkison’s Disease (AD/PD 2024) taking place in Lisbon, Portugal from March 5-9, 2024.
  • Title: Oral Simufilam in Mild-to-moderate Alzheimer’s Disease: Baseline Characteristics in RETHINK and REFOCUS Phase 3 Trials.
  • Overview: Cassava Sciences’ simufilam is a novel, small molecule drug candidate for the proposed treatment of Alzheimer’s disease dementia.
  • Date, Time and Location: This presentation will be available on Tuesday, March 5th, at 8:00 am Eastern time at www.CassavaSciences.com , under the tabs ‘Investors/Company Presentation,’ and may also be available on the AD/PD 2024 conference platform.

Aruna BIO Establishes Stroke Advisory Board to Advance Lead Program, AB126 into the Clinic

Retrieved on: 
Monday, March 4, 2024

BOSTON and ATHENS, Ga., March 04, 2024 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in neural exosome-based therapeutics for the treatment of neurodegenerative diseases, is pleased to announce the formation of its Stroke Advisory Board (SAB). Comprising distinguished experts in fields of neurology, stroke research, and clinical development, the board underscores Aruna Bio’s commitment to advancing its clinical development program with unparalleled expertise.

Key Points: 
  • Comprising distinguished experts in fields of neurology, stroke research, and clinical development, the board underscores Aruna Bio’s commitment to advancing its clinical development program with unparalleled expertise.
  • The newly established board features renowned figures in the medical and scientific community, each bringing a wealth of knowledge and experience to Aruna Bio.
  • “AB126 is making history with the first exosome therapy to enter human clinical trials for a neurological condition,” said Stephen From, Chief Executive Officer at Aruna Bio.
  • “This represents a significant step forward in our quest to transform the treatment landscape for stroke and other neurodegenerative diseases.

DiagnaMed Announces Test Launch of CERVAI™ Brain Health in University Brain Health Center

Retrieved on: 
Wednesday, February 28, 2024

TORONTO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a digital health artificial intelligence company focused on brain health, today announced a test launch of CERVAI™, a world-first consumer brain health and wellness AI solution, at the University of Miami Comprehensive Center for Brain Health.

Key Points: 
  • TORONTO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a digital health artificial intelligence company focused on brain health, today announced a test launch of CERVAI™, a world-first consumer brain health and wellness AI solution, at the University of Miami Comprehensive Center for Brain Health.
  • The initial focus will be evaluating the brain health assessment portion of CERVAI™, which scores brain health by taking a clinically validated assessment for brain resilience, vulnerability and performance functions.
  • Essentially, it is intended to “take a snapshot” of a patient’s brain health.
  • The CERVAI™ Brain Health test pilot program continues to be open to a select 25 clinics in the U.S. and Canada.

Reliq Health Technologies, Inc. Announces Expansion of Mental Health Services

Retrieved on: 
Tuesday, February 27, 2024

“We are very pleased to be adding cognitive assessments to our portfolio of mental health services,” said Chris Shields, CEO at Reliq Health Technologies, Inc. “Many of our existing and potential clients have requested that Reliq offer additional products and services in the mental healthcare area, particularly for patients in Skilled Nursing and Assisted Living Facilities.

Key Points: 
  • “We are very pleased to be adding cognitive assessments to our portfolio of mental health services,” said Chris Shields, CEO at Reliq Health Technologies, Inc. “Many of our existing and potential clients have requested that Reliq offer additional products and services in the mental healthcare area, particularly for patients in Skilled Nursing and Assisted Living Facilities.
  • Providing cognitive assessments to our patient populations, will allow clinicians to identify patients with previously undiagnosed mental health needs.
  • Medicare has increased the reimbursement rate for Behavioral Health Integration (BHI) by 25% in 2024 as part of their ongoing commitment to improving mental health in at-risk patient populations.
  • The Company will initially roll out its expanded mental health services to existing Skilled Nursing and Assisted Living Facilities as well as Alzheimer and Dementia Care (Memory Care) Facilities.